Innovative Surgical Sciences最新文献_第2页

The evolving role of esophageal surgery - advancements, challenges, and the path forward. 食道手术的角色演变-进展，挑战和前进的道路。

IF 1.7

Innovative Surgical Sciences Pub Date : 2025-03-03 eCollection Date: 2025-03-01 DOI: 10.1515/iss-2025-0005

Stefan P Mönig, Mickael Chevallay

引用次数: 0

What is the best surgical approach for esophageal cancer? 食管癌最好的手术方式是什么？

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-12-06 eCollection Date: 2025-03-01 DOI: 10.1515/iss-2023-0021

Verena Tripke, Vladimir J Lozanovski, Carolina Mann, Hauke Lang, Peter P Grimminger

{"title":"What is the best surgical approach for esophageal cancer?","authors":"Verena Tripke, Vladimir J Lozanovski, Carolina Mann, Hauke Lang, Peter P Grimminger","doi":"10.1515/iss-2023-0021","DOIUrl":"10.1515/iss-2023-0021","url":null,"abstract":"Esophageal cancer is an aggressive tumor entity, and oncologic esophagectomy with two-field lymphadenectomy after perioperative chemotherapy or chemoradiotherapy is the standard of care for curative treatment. Oncological esophagectomy is a complex procedure associated with a relevant surgical trauma. Complications, such as severe pulmonary infections and anastomotic leakage with mediastinitis lead to a high morbidity rate. To reduce the surgical trauma, the minimally invasive technique was introduced in esophageal surgery. Minimally invasive esophagectomy is associated with less postoperative pain and a reduced rate of pulmonary infections. Currently, there are two major different totally minimally invasive techniques, the conventional laparoscopic/thoracoscopic approach (MIE) and the robotic assisted approach (RAMIE). Both methods require teaching due to the flat learning curve associated with these complex procedures. However, both MIE and RAMIE are performed safely in specialized centers. They are associated with improved short-term outcome and similar oncological outcome compared to open esophagectomy. The robotic assisted approach has additional benefits that may be supported by the results of more randomized controlled trials in the future.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"10 1","pages":"31-35"},"PeriodicalIF":1.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant treatment of esophageal cancer: chemotherapy, chemoradiation, immunotherapy, and future trends of therapy. 食管癌的新辅助治疗：化疗、放化疗、免疫治疗及治疗的未来趋势。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-11-25 eCollection Date: 2025-03-01 DOI: 10.1515/iss-2023-0005

Freschta Malekzada, Miljana Vladimiriov, Michael Leitz, Julia Michel, Fabian Nimzewski, Jens Hoeppner

{"title":"Neoadjuvant treatment of esophageal cancer: chemotherapy, chemoradiation, immunotherapy, and future trends of therapy.","authors":"Freschta Malekzada, Miljana Vladimiriov, Michael Leitz, Julia Michel, Fabian Nimzewski, Jens Hoeppner","doi":"10.1515/iss-2023-0005","DOIUrl":"10.1515/iss-2023-0005","url":null,"abstract":"In the Western hemisphere, nonmetastatic locally advanced esophageal carcinoma is mostly treated in multimodal therapy protocols according to current therapy guidelines. In squamous cell carcinoma of the esophagus, neoadjuvant chemoradiation is the favorable option. Unimodal surgical and chemoradiation treatment alternatives show inferior results on this entity. For locally advanced adenocarcinoma of the esophagus perioperative chemotherapy and neoadjuvant chemoradiation have been competing treatment approaches in the recent past. Both are evidence based (class I evidence) and superior compared to unimodal surgery. However, the latest results of head-to-head comparative therapy studies show superior overall survival results for the FLOT regimen of perioperative chemotherapy. Furthermore, immunotherapy and targeted therapy with monoclonal antibodies have become a strong focus of current clinical research. Nivolumab as well as trastuzumab are already an important part of the current standard therapies. In both entities - SCC and AC - a significant quota of patients shows a locoregional complete remission of the tumor in the specimen after modern neoadjuvant therapy and surgical resection. The addition of immunotherapy and targeted therapy to neoadjuvant therapy further increases complete remission rates in defined subgroups according to the results of current studies. Currently, three prospective randomized trials are ongoing on the subject of future possibilities for organ-preserving concepts in case of complete clinical remission (\"surgery as needed,\" \"watch and wait\"). It is to be expected for the future that curative short-term and long-term treatment results in locally advanced esophageal carcinoma will significantly improve, particularly due to the additional possibilities of immunotherapy and organ-preserving therapy concepts in postneoadjuvant complete remission.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"10 1","pages":"3-9"},"PeriodicalIF":1.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Periprosthetic joint infections - a scoping review. 假体周围关节感染-范围综述。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-11-20 eCollection Date: 2024-12-01 DOI: 10.1515/iss-2024-0016

Yasmin Youssef, Annika Hättich, Kim Lydia Klepka

引用次数: 0

What's new in surgery? Essentials 2024 - young patients and fast decisions. 外科手术有什么新进展？2024年要点：年轻患者和快速决策。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-11-15 eCollection Date: 2024-12-01 DOI: 10.1515/iss-2024-0038

Juliane Kröplin

引用次数: 0

Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer. 食管癌和胃食管癌新辅助放化疗后临床反应完全的患者的主动监测。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-11-07 eCollection Date: 2025-03-01 DOI: 10.1515/iss-2023-0010

Tamara J Huizer, Sjoerd M Lagarde, Joost J M E Nuyttens, Lindsey Oudijk, Manon C W Spaander, Roelf Valkema, Bianca Mostert, Bas P L Wijnhoven

{"title":"Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer.","authors":"Tamara J Huizer, Sjoerd M Lagarde, Joost J M E Nuyttens, Lindsey Oudijk, Manon C W Spaander, Roelf Valkema, Bianca Mostert, Bas P L Wijnhoven","doi":"10.1515/iss-2023-0010","DOIUrl":"10.1515/iss-2023-0010","url":null,"abstract":"Neoadjuvant chemoradiotherapy in patients with esophageal- and gastroesophageal junction cancer induces tumor regression. In approximately one fourth of patients, this leads to a pathological complete response in the resection specimen. Hence, active surveillance may be an alternative strategy in patients without residual disease after neoadjuvant chemoradiotherapy. Previous studies have shown that the combination of esophagogastroduodenoscopy with bite-on-bite biopsies, endoscopic ultrasound with fine needle aspiration of suspected lymph nodes, and a PET-CT-scan can be considered adequate for the detection of residual disease. So far, it has been unclear whether active surveillance with surgery as needed is a safe treatment option and leads to non-inferior overall survival compared to standard esophagectomy after neoadjuvant chemoradiotherapy. This review will discuss the current status of active surveillance for esophageal and junctional cancer.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"10 1","pages":"11-19"},"PeriodicalIF":1.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of different parameters on the outcome of vv-ECMO therapy in burn patients - a retrospective cohort study from a burn and high output ECMO center. 不同参数对烧伤患者vv-ECMO治疗结果的影响——一项来自烧伤和高输出ECMO中心的回顾性队列研究

IF 1.2

Innovative Surgical Sciences Pub Date : 2024-09-16 eCollection Date: 2025-06-01 DOI: 10.1515/iss-2024-0024

Alperen S Bingoel, Frederik Schlottmann, Clarissa Plinke, Khaled Dastagir, Doha Obed, Anieto Enechukwu, Thorben Dieck, Lukas Wellkamp, Jasmin Sarah Hanke, Christian Kühn, Arjang Ruhparwar, Nicco Krezdorn, Peter M Vogt

{"title":"Impact of different parameters on the outcome of vv-ECMO therapy in burn patients - a retrospective cohort study from a burn and high output ECMO center.","authors":"Alperen S Bingoel, Frederik Schlottmann, Clarissa Plinke, Khaled Dastagir, Doha Obed, Anieto Enechukwu, Thorben Dieck, Lukas Wellkamp, Jasmin Sarah Hanke, Christian Kühn, Arjang Ruhparwar, Nicco Krezdorn, Peter M Vogt","doi":"10.1515/iss-2024-0024","DOIUrl":"10.1515/iss-2024-0024","url":null,"abstract":"Objectives: The treatment of acute respiratory distress syndrome (ARDS) in burn patients remains a major challenge. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) is a standard treatment for severe ARDS today. But reports on survival outcome in burn patients remain variable in the literature. The aim of this study is to identify factors that may influence survival and therapy outcomes in this distinct patient population.Methods: A single-center retrospective study was conducted in the burn intensive care unit (BICU). Inclusion criteria were the use of vv-ECMO for ARDS after burn injuries. The data analyzed included general medical data and various parameters from the BICU.Results: Between January 2012 and December 2022, 21 consecutive adult patients were identified who underwent vv-ECMO treatment. Five patients (24 %) survived the therapy and could be discharged, and 16 patients (76 %) succumbed to their disease. A higher TBSA affected, lower pH in arterial blood gas analysis after 24 and 36 h, multiorgan dysfunction syndrome (MODS), renal insufficiency, and renal replacement therapy were significantly associated with a lethal outcome.Conclusions: The data from the present study showed an overall mortality rate of 76 %, which is unsatisfactory compared to the literature. This could be explained by complicating factors such as MODS, renal failure, and renal replacement therapy. However, the indication for vv-ECMO must be adapted to the individual situation of the respective patient. Due to the additional higher risk for complications, the utilization of ECMO therapy should be reserved for specialized burn centers with an interdisciplinary setting.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"10 2","pages":"73-80"},"PeriodicalIF":1.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy as a new perspective for the therapy of esophageal cancer. 免疫疗法作为食管癌治疗的新前景。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-09-09 eCollection Date: 2025-03-01 DOI: 10.1515/iss-2023-0023

Yvonne Huber, Markus Moehler, Anica Högner

{"title":"Immunotherapy as a new perspective for the therapy of esophageal cancer.","authors":"Yvonne Huber, Markus Moehler, Anica Högner","doi":"10.1515/iss-2023-0023","DOIUrl":"10.1515/iss-2023-0023","url":null,"abstract":"The therapeutic landscape in nearly every therapeutic line in advanced/metastatic patients with squamous cell carcinoma (SCC) and esophagogastric adenocarcinoma (EGC) is enriched by recent approvals of immune checkpoint inhibitors (ICIs). In curative intended therapy, patients without pathological residual disease of SCC or GEJ (esophagogastric junction) cancer after preoperative chemoradiation and complete resection have access to adjuvant immunotherapy (independent of PD-L1 (programmed cell death protein 1) status, nivolumab, CHECKMATE 577). For metastatic SCC in the first-line, nivolumab combined with chemotherapy or with ipilimumab (TPS (tumor proportion score) ≥1 %, SCC, CHECKMATE 648) are approved, as well as second-line nivolumab alone regardless of PD-L1 status (ATTRACTION 03). For both, locally advanced or metastatic SCC and EGC, chemotherapy with pembrolizumab is available for patients with CPS (combined positive score) ≥10 (KEYNOTE 590) and for adenocarcinoma with nivolumab (CPS ≥5, CHECKMATE 649). Recent added approvals are chemotherapy with pembrolizumab in CPS ≥1 patients (KEYNOTE 859) and the addition of trastuzumab for personalized therapy in HER-2 positive/CPS ≥1 gastric and GEJ patients (KEYNOTE 811).","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"10 1","pages":"37-41"},"PeriodicalIF":1.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A narrative review of present knowledge and digital approaches in orthognathic surgery. 叙述回顾目前的知识和数字方法在正颌手术。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-09-06 eCollection Date: 2024-12-01 DOI: 10.1515/iss-2024-0018

Constanze Friedrich, Constantin Graw, Juliane Kröplin

{"title":"A narrative review of present knowledge and digital approaches in orthognathic surgery.","authors":"Constanze Friedrich, Constantin Graw, Juliane Kröplin","doi":"10.1515/iss-2024-0018","DOIUrl":"10.1515/iss-2024-0018","url":null,"abstract":"Introduction: Anomalies of jaw position and shape affect approximately 10 % of the population. They can have a significant impact on quality of life, which is why the continuous improvement of therapeutic approaches is a key concern in oral and maxillofacial surgery. The aim of this narrative review article is to examine the development of orthognathic surgery in the context of traditional and innovative methods.Content: A Pubmed-based selective literature search was performed considering literature predominantly from 2022 to 2023. Search terms were \"orthognathic surgery\" in combination with \"virtual surgical planning\" and \"3D printing\".Summary: Depending on the extent of the existing anomalies, there are purely orthodontic or combined orthodontic-surgical treatment approaches. Technological innovations in particular are changing both the therapeutic approach and the planning of surgical treatment to an almost completely digital workflow. This change can lead to greater precision in treatment and more efficient planning, resulting in reduced costs and an overall improvement in clinical outcomes, including patient satisfaction.Outlook: This study presents an overview of the field of orthognathic surgery and discusses developments and challenges for the future. With traditional approaches being time-consuming and prone to error digital technologies like VSP, AI and PSIs improve accuracy and efficiency, though challenges persist.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"9 4","pages":"175-179"},"PeriodicalIF":1.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update burn surgery: overview of current multidisciplinary treatment concepts. 更新烧伤手术：当前多学科治疗概念概述。

IF 1.7

Innovative Surgical Sciences Pub Date : 2024-08-23 eCollection Date: 2024-12-01 DOI: 10.1515/iss-2024-0020

Frederik Schlottmann, Lisa Lorbeer

{"title":"Update burn surgery: overview of current multidisciplinary treatment concepts.","authors":"Frederik Schlottmann, Lisa Lorbeer","doi":"10.1515/iss-2024-0020","DOIUrl":"10.1515/iss-2024-0020","url":null,"abstract":"The treatment of severe burn injuries is an essential part of plastic-reconstructive surgery. Severe burned patients are treated in burn centers, which have highly specialized technical and personnel equipment. In addition to clear recommendations for prehospital management, intensive care therapy is usually required for extensive burn wounds. Shock therapy in burns primarily involves balanced fluid resuscitation according to hemodynamic monitoring, vasopressor support, pain management, temperature regulation, oxygen therapy, and comprehensive supportive care to stabilize the patient's condition. Surgical treatment is still based on wound debridement and the gold standard of autologous split-thickness skin grafting. Besides skin transplantation, surgical management of burns may also involve the application of various topical therapies to promote wound healing, reduce pain, and prevent infection. These therapies may include antimicrobial dressings, skin substitutes, growth factors, or specialized wound care products. Once the acute treatment has been completed, multidisciplinary rehabilitation treatment takes place, which begins in the acute hospital and continues in the outpatient and inpatient rehabilitation areas. Surgical treatment of the secondary complications of burns and scars is also an important component of burn care. Comprehensive knowledge of the various components and players involved in the care of severely burned patients is, therefore, required in order to achieve the best possible outcome for the patient.","PeriodicalId":44186,"journal":{"name":"Innovative Surgical Sciences","volume":"9 4","pages":"181-190"},"PeriodicalIF":1.7,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0